NASDAQ
DRIO
Last Price
US $6.77
Valuation
Financial
Performance
Cash flow to debt coverage
DarioHealth Corp. cash flow to debt ratio of -81.71% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
DarioHealth Corp.'s free cash flow has increased -32.60% from $-38.70M last year to $-26.08M, signaling increasing performance
Debt-to-equity ratio
DarioHealth Corp.'s debt to equity ratio is 0.59, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
DarioHealth Corp.'s debt has increased relative to shareholder equity from 0.42 last year to 0.59 today, signaling weakened financials
Net debt to EBITDA
DarioHealth Corp. has negative EBITDA, making leverage ratio unreliable
Interest coverage
DarioHealth Corp.'s interest coverage ratio is -12.36, which means that the company struggles to meet interest obligations, signaling financial risk.
Profit margin growth
DarioHealth Corp.'s profit margin has increased (-304.17%) in the last year from -158.09% to 322.77%, signaling increasing performance
Current ratio
DarioHealth Corp.'s short-term assets of $34.81M exceed its short-term liabilities of $9.32M
Return on assets
DarioHealth Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
DarioHealth Corp.'s return on equity of 104.15%, is higher than 15.00%, indicating good performance
Earnings quality
DarioHealth Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
DarioHealth Corp. had positive net income in only 0 out of 5 years, indicating unstable earnings
Positive free cash flow
DarioHealth Corp. has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
DarioHealth Corp. has negative free cash flow, indicating cash burn
Earnings growth
DarioHealth Corp.'s yearly earnings has increased -2.42% since last year from $-42.75M to $-41.71M, signaling increasing performance
Revenue growth
DarioHealth Corp.'s yearly revenue has decreased 17.31% since last year from $27.04M to $22.36M, signaling decreasing performance
Return on invested capital
ROIC -78.42% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
DarioHealth Corp.'s 3-year revenue CAGR of -6.84% is negative, indicating declining revenue over the past 3 years
Revenue consistency
DarioHealth Corp. had revenue growth in 3 out of 5 years, indicating consistent revenue performance
Return on equity consistency
DarioHealth Corp. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity
Cash Flow Valuation (DCF)
DarioHealth Corp. has insufficient data to evaluate this check.
Earnings yield (TTM)
DarioHealth Corp. has an earnings yield of 107.15%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
EBITDA Valuation
DarioHealth Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
DarioHealth Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
DarioHealth Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
DarioHealth Corp. has a price-to-book ratio of 1.15x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
DarioHealth Corp. has a price-to-sales ratio of 3.01x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
104.15%
Return on equity
ROIC: -78.42%
Valuation History
11.0X
Price to Earnings
EV/EBITDA: -2.7X
Cash flow
Profit margin
GROWTH (5Y CAGR)
Revenue
24.17%
EBITDA
-3.05%
Cash flow
-7.30%
Fair Value
Market $6.77
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.